Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
Clinical trial's full patient number recruitment moves Solexan™ forward as a new therapy option for shingles sufferers, a debilitating and painful viral infection.
Wintermute Biomedical is pleased to announce the successful recruitment, and completion of treatment, for all participants in its Phase Ib clinical trial—a double-blind, placebo-controlled study investigating Solexan™ for the treatment of shingles.
Wintermute is delighted that there were no reported serious adverse events (SAEs).
This important milestone marks significant progress in the development of Solexan™, a topical antiviral and pain-relieving therapy designed to address the need for additional treatment options for shingles.
Wintermute Biomedical has extend its sincere thanks to the clinical partners, investigators, and patients whose commitment made this achievement possible.
Unblinded trial results are anticipated in the coming weeks.